Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients

Journal of Pharmaceutical Sciences

Volumn 104, Issue 9, 2015, Pages 3194-3198

  Matsuo, Yumiko ^a   Ishibashi, Toru ^a   Shimamura, Kenji ^a   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

antiinfectives; clinical pharmacokinetics; doripenem; Monte Carlo; pediatric; pharmacodynamics

Indexed keywords

DORIPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OTITIS MEDIA; PEDIATRICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREDICTION; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADULT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CHILD; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; STREPTOCOCCUS PNEUMONIAE;

EID: 84939160711     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24432     Document Type: Article

References (28)

1. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL,. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis 44: 79-86.
2. Durusano GL,. 2003. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 36 (Suppl 1): S42-S50.
3. Nicolau DP,. 2003. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 9: 292-296.
4. Ellis JM, Kuti JL, Nicolau DP,. 2006. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: A report from the OPTAMA program. Pediatr Drugs 8: 131-138.
5. Kuti JL, Nightingale CH, Nicolau DP,. 2004. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 48: 2464-2470.
6. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP,. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43: 1116-1123.
7. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT,. 2008. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacteria isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 52: 761-766.
8. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA,. 2007. Comparative review of the carbapenems. Drugs 67: 1027-1052.
9. Tsuji M, Furuya N, Matsumoto T, Ishii Y, Ohno A, Tateda K, Miyazaki S, Yamaguchi K,. 2005. In vitro and in vivo antibacterial activity of doripenem, a new carbepenem. Jpn J Chemother 53 (S-1): 1-16.
10. Kuwahara-Arai K, Hiramatsu K,. 2005. In vitro activity of doripenem against gram-positive and gram-negative bacteria isolates. Jpn J Chemother 53 (S-1): 17-23.
11. Miwa H, Kimura Y, Jinushi Y, Fujimura T, Nishikawa T, Munekage T, Kuroda N, Yamano Y, Tsuji M, Okazaki K, Sato T, Matsuda H,. 2005. Antipseudomonal activity of doripenem, a novel parenteral carbapenem antibiotic. Jpn J Chemother 53 (S-1): 80-91.
12. Finibax Japanese package insert. Accessed on, at: http://www.info.pmda.go.jp/go/pack/6139402D1032-1-04/
13. Wajima T, Shimada J, Ishibashi T, Kubota R, Matsuo Y,. 2010. Pharmacokinetics of doripenem at 1 g and 2 g in healthy volunteers and patients with serious infection. Poster presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, Massachusetts; September, 2010.
14. Boxenbaum H,. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharm Biopharm 10: 201-227.
15. Mahmood I,. 2005. Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Maryland: Pine House Publishers.
16. Holford NHG,. 1996. A size standard for pharmacokinetics. Clin Pharm 30: 329-332.
17. Anderson BJ, McKee AD, Holford NHG,. 1997. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharm 33: 313-327.
18. Shimamura K, Wajima T, Yoshitaka Y,. 2007. Pharmacokinetic prediction for intravenous β-lactam antibiotics in pediatric patients. J Pharm Sci 96: 3125-3139.
19. Boeckmann AJ, Sheiner LB, Beal SL,. 1992. NONMEM users guide. San Francisco, California: NONMEM Project Group University of California.
20. Nakashima M, Oguma T,. 2005. Phase 1 study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers. Jpn J Chemother 53 (S-1): 104-123.
21. Wajima T, Yano Y, Fukumura K, Oguma T,. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93: 1890-1900.
22. Nandy P, Samtani MN, Lin R,. 2010. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 54: 2354-2359.
23. Toyonaga Y, Sunakawa K, Motohiro T, Iwai N, Tanigawara Y, Endo H, Sato Y, Kuroki H, Minagawa M, Ishiwada N, Tajima T, Iwata S, Cho H, Sunaoshi W, Kato T, Bamba M, Wakamiya E, Sugita K, Yamazaki T, Kawamura N, Haruta T, Furukawa S, Okada T, Fujimoto T, Ishihara T, Ando A, Tsumura N,. 2003. Clinical study of meropenem for infections in the pediatric field. Jpn J Chemother 51: 762-781.
24. Fujimura T, Yoshida I, Itoh Y, Tachibana M, Kaku M, Kanemitsu K, Takahashi C, Shiotani J, Ono Y, Baba H, Matsuo S, Asari S, Matsuoka K, Kusano N, Nose M, Saikawa T, Hiramatsu K, Kohno S, Hirakata Y, Yamane N, Nakasone I, Yamano Y,. 2008. Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2004. Jpn J Chemother 56: 543-561.
25. Yoshida I, Fujimura T, Itoh Y, Tachibana M, Kaku M, Kanemitsu K, Takahashi C, Shiotani J, Ono Y, Baba H, Matsuo S, Asari S, Matsuoka K, Kusano N, Nose M, Saikawa T, Hiramatsu K, Kohno S, Hirakata Y, Yamane N, Nakasone I, Yamano Y,. 2008. Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2004. Jpn J Chemother 56: 562-579.
26. Totsuka K, Wajima T, Katsube T, Sakata H, Iwata S, Haruta T, Tsumura N, Suzuki K, Sunakawa K,. 2011. Pharmacokinetics/pharmacodynamics of doripenem (DRPM) in Japanese pediatric patients. Poster presented at 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois, September, 2011.
27. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. Guidance for industry: Exposure-response relationships-Study design, data analysis, and regulatory applications. Accessed on, at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf
28. Sunakawa K, Sakata H, Iwata S, Haruta T, Tsumura N, Suzuki K, Totsuka K,. 2011. Efficacy and safety of doripenem (DRPM) in pediatric patients. Poster presented at 51th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois, September, 2011.